Kingdon Capital Management L.L.C. purchased a new stake in Shire PLC (NASDAQ:SHPG) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 62,935 shares of the biopharmaceutical company’s stock, valued at approximately $10,401,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Inspirion Wealth Advisors LLC increased its position in shares of Shire PLC by 0.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 8 shares during the period. Synovus Financial Corp increased its position in shares of Shire PLC by 0.4% during the second quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 11 shares during the period. Level Four Advisory Services LLC increased its position in shares of Shire PLC by 0.5% during the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 13 shares during the period. Baldwin Investment Management LLC increased its position in shares of Shire PLC by 1.4% during the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 23 shares during the period. Finally, Hartford Financial Management Inc. increased its position in shares of Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares during the period. Hedge funds and other institutional investors own 19.28% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a research report on Monday. Cantor Fitzgerald reiterated a “buy” rating and set a $222.00 price objective on shares of Shire PLC in a research report on Thursday, September 14th. ValuEngine cut shares of Shire PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Evercore ISI assumed coverage on shares of Shire PLC in a research report on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price objective for the company. Finally, Barclays PLC cut shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $220.91.

Shire PLC (NASDAQ SHPG) traded down 1.38% on Friday, hitting $151.03. 400,912 shares of the company were exchanged. Shire PLC has a 52 week low of $139.36 and a 52 week high of $198.58.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Analysts anticipate that Shire PLC will post $14.93 EPS for the current fiscal year.

The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 41.07%.

COPYRIGHT VIOLATION WARNING: “62,935 Shares in Shire PLC (SHPG) Acquired by Kingdon Capital Management L.L.C.” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/62935-shares-in-shire-plc-shpg-acquired-by-kingdon-capital-management-l-l-c.html.

Shire PLC Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.